VP1-2025: Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Final overall survival (OS) from the phase III TROPION-Breast01 trial
医学
转移性乳腺癌
化疗
肿瘤科
乳腺癌
内科学
激素受体
癌症
HER2阴性
乳腺
作者
Barbara Pistilli,Komal Jhaveri,S-A. Im,Sònia Pernas,Michelino De Laurentiis,Shuhua Wang,Noelia Martínez-Jáñez,Giuliano Santos Borges,David W. Cescon,Masaya Hattori,Yen‐Shen Lu,E. Hamilton,Qiang Zhang,J. Tsurutani,Kevin Kalinsky,Linhong Xu,Sabrina Khan,H.S. Rugo,B. Xu,Amit Bardia
PDF的下载单位、IP信息已删除
(2025-6-4)
科研通AI6.2
charint
ceeray23
Ava
皖公网安备34019202002308
